HIV type 1 vaccines for worldwide use: Predicting in-clade and cross-clade breadth of immune responses

AIDS Research and Human Retroviruses

Volumn 23, Issue 10, 2007, Pages 1283-1292

  Finnefrock, Adam C ^a   Liu, Xiaomei ^a   Opalka, David W ^a   Shiver, John W ^a   Casimiro, Danilo R ^a   Condra, Jon H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; EPITOPE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NEF PROTEIN; POL PROTEIN; TRANSACTIVATOR PROTEIN; VIRUS ENVELOPE PROTEIN;

ALGORITHM; AMINO ACID SEQUENCE; ARTICLE; CELLULAR IMMUNITY; CONSENSUS SEQUENCE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IMMUNE RESPONSE; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; T LYMPHOCYTE;

AIDS VACCINES; AMINO ACID SEQUENCE; EPITOPE MAPPING; GENE PRODUCTS, ENV; GENE PRODUCTS, GAG; GENE PRODUCTS, NEF; GENE PRODUCTS, POL; HIV ANTIGENS; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA;

EID: 35548978665     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0098     Document Type: Article

References (31)

1. Gottlieb MS, Schroff R, Schanker HM, et al.: Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: Evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981;305:1425-1431.
2. Masur H, Michelis MA, Greene JB, et al.: An outbreak of community-acquired Pneumocystis carinii pneumonia: Initial manifestation of cellular immune dysfunction. N Engl J Med 1981;305:1431-1438.
3. Barre-Sinoussi F, Chermann JC, Rey F, et al.: Isolation of a Tlymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868-871.
4. Popovic M, Sarngadharan MG, Read E, and Gallo RC: Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984;224:497-500.
5. Levy JA, Hoffman AD, Kramer SM, Landis JA, Shimabukuro JM, and Oshiro LS: Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science 1984;225:840-842.
6. Koup RA, Safrit JT, Cao Y, et al.: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68:4650-4655.
7. Shiver JW, Fu TM, Chen L, et al.: Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002;415:331-335.
8. Girard MP, Osmanov SK, and Kieny MP: A review of vaccine research and development: The human immunodeficiency virus (HIV). Vaccine 2006;24:4062-4081.
9. McCutchan FE, Viputtigul K, de Souza MS, et al.: Diversity of envelope glycoprotein from human immunodeficiency virus type 1 of recent seroconverters in Thailand. AIDS Res Hum Retroviruses 2000;16:801-805.
10. McCutchan FE: Global epidemiology of HIV. J Med Virol 2006;78(Suppl. 1):S7-S12.
11. Leitner T, Foley B, Hahn B, et al.: HIV Sequence Compendium 2005. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, 2005.
12. Zhan X, Martin LN, Slobod KS, et al.: Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV. Vaccine 2005;23:5306-5320.
13. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, and Detours V: Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 2001;58:19-42.
14. Gaschen B, Taylor J, Yusim K, et al.: Diversity considerations in HIV-1 vaccine selection. Science 2002;296:2354-2360.
15. Nickle DC, Jensen MA, Gottlieb GS, et al.: Consensus and ancestral state HIV vaccines. Science 2003;299:1515-1518; author reply 1515-1518.
16. Mullins JI, Nickle DC, Heath L, Rodrigo AG, and Learn GH: Immunogen sequence: The fourth tier of AIDS vaccine design. Expert Rev Vaccines 2004;3:S151-159.
17. Needleman SB and Wunsch CD: A general method applicable to the search for similarities in the amino acid sequence of two proteins. J Mol Biol 1970;48:443-453.
18. Rice P, Longden I, and Bleasby A: EMBOSS: The European Molecular Biology Open Software Suite. Trends Genet 2000;16:276-277.
19. Rao JM: New scoring matrix for amino acid residue exchanges based on residue characteristic physical parameters. Int J Pept Protein Res 1987;29:276-281.
20. Osmanov S, Pattou C, Walker N, Schwardlander B, and Esparza J: Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr 2002;29:184-190.
21. Coplan PM, Gupta SB, Dubey SA, et al.: Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents. J Infect Dis 2005;191:1427-1434.
22. Fu T-M, Dubey SA, Mehrotra DV, et al.: Evaluation of cellular immune responses in subjects chronically infected with HIV-1. AIDS Res Hum Retroviruses 2007;23:67-76.
23. UNAIDS: 2006 Report on the global AIDS epidemic. At http://www.unaids. org/en/HIV_data/2006GlobalReport/default.asp, 2006.
24. Clark GL and Vinters HV: Dementia and ataxia in a patient with AIDS. West J Med 1987;146:68-72.
25. Koyanagi Y, Miles S, Mitsuyasu RT, Merrill JE, Vinters HV, and Chen IS: Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 1987;236:819-822.
26. Korber B, Muldoon M, Theiler J, et al.: Timing the ancestor of the HIV-1 pandemic strains. Science 2000;288:1789-1796.
27. Visawapoka U, Tovanabutra S, Currier JR, et al.: Circulating and unique recombinant forms of HIV type 1 containing subsubtype A2. AIDS Res Hum Retroviruses 2006;22:695-702.
28. Currier JR, Visawapoka U, Tovanabutra S, et al.: CTL epitope distribution patterns in the Gag and Nef proteins of HIV-1 from subtype A infected subjects in Kenya: Use of multiple peptide sets increases the detectable breadth of the CTL response. BMC Immunol 2006;7:8.
29. Karlsson AC, Martin JN, Younger SR, et al.: Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J Immunol Methods 2003;283:141-153.
30. Suni MA, Dunn HS, Orr PL, et al.: Performance of plate-based cytokine flow cytometry with automated data analysis. BMC Immunol 2003;4:9.
31. Fischer W, Perkins S, Theiler J, et al.: Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 2007;13:100-106.